The goal of this observational study is to register hematologic patients with haploidentical hematopoietic stem cell transplantation (haploHSCT). The main questions it aims to answer are:
* 1-year progression free survival rate * 1-year overall survival rate * Graft-versus-host free relapsed free survival at 30-day, 100-day, 180-day and 1-year * Chronic Graft-versus-host free relapsed free survival at 180-day and 1-year * Rate of Neutrophil and platelet engraftment * Efficacy of donor specific antibody desensitization * Relapsed rate * Primary and late graft failure * Safety and complication of haploHSCT * Complication of viral, bacterial, and fungal infection * Viral reactivation * Comparison outcomes between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT * Comparison cost-effectiveness of treatment between matched sibling donor (MSD) HSCT and matched unrelated donor (MUD) HSCT Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.
Patients diagnosed with hematologic diseases indicated for treatment with haploidentical hematopoietic stem cell transplantation including
Myeloid diseases (acute myeloblastic leukemia, myelodysplastic syndrome, chronic myelocytic leukemia, classical and non-classical myeloproliferative disorders)
Lymphoid disease (acute lymphoblastic leukemia, lymphoma)
severe aplastic anemia
HIV infection, active hepatitis B, active hepatitis C
active infection
history of other malignancy except basal cell carcinoma and carcinoma of the cervix in situ
A pregnant woman and/or refusal of contraception
hematologic patients with haploidentical hematopoietic stem cell transplantation
Cohort
Prospective
Not listed
register hematologic patients with haploidentical hematopoietic stem cell transplantation
progression free survival rate
overall survival rate
Chronic Graft-versus-host free relapsed free survival
Relapsed rate
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
